JP2015532096A5 - - Google Patents

Download PDF

Info

Publication number
JP2015532096A5
JP2015532096A5 JP2015534771A JP2015534771A JP2015532096A5 JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5 JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
aoi
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534771A
Other languages
English (en)
Other versions
JP6351598B2 (ja
JP2015532096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062410 external-priority patent/WO2014055370A1/en
Publication of JP2015532096A publication Critical patent/JP2015532096A/ja
Publication of JP2015532096A5 publication Critical patent/JP2015532096A5/ja
Application granted granted Critical
Publication of JP6351598B2 publication Critical patent/JP6351598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 対象の抗体(「AOI」)を産生する方法であって、AOIの発現および分泌に適した条件下で5mMから30mMの間の濃度にてグリシンを含む細胞培養培地中でAOIを分泌し、発現するように操作されたNSO細胞を培養し、それによりAOIを産生することを含む、方法。
  2. グリシンの濃度が10mMから25mM、または15mMから20mMまたは16mMから18mMの範囲である、請求項1に記載の方法。
  3. 培地が無タンパク質培地である、請求項1または2に記載の方法。
  4. AOIを回収することをさらに含む、請求項1からのいずれか一項に記載の方法。
  5. AOIを回収することが、培養培地からNSO細胞を分離する工程を含み、AOIを精製することをさらに含んでもよい、請求項に記載の方法。
  6. NSO細胞が、培養する前に1.5×10細胞/mLから2.5×10細胞/mLの密度で播種される、請求項1からのいずれか一項に記載の方法。
  7. AOIが、配列番号1のアミノ酸配列のVH領域および配列番号2のアミノ酸配列のVL領域を含むIgG1モノクローナル抗体である、請求項1からのいずれか一項に記載の方法であって、AOIが、配列番号3の完全重鎖アミノ酸配列および配列番号4の完全軽鎖アミノ酸配列を有してもよい方法。
  8. AOIが、配列番号5のアミノ酸配列のVH領域および配列番号6のアミノ酸配列のVL領域を含むIgG1モノクローナル抗体である、請求項1からのいずれか一項に記載の方法。
  9. AOIが、配列番号7の完全重鎖アミノ酸配列および配列番号8の完全軽鎖アミノ酸配列を有する、請求項に記載の方法。
  10. AOIが、配列番号9のアミノ酸配列のVH領域および配列番号10のアミノ酸配列のVL領域を含むIgG1モノクローナル抗体である、請求項1からのいずれか一項に記載の方法。
  11. AOIが、配列番号11の完全重鎖アミノ酸配列および配列番号12の完全軽鎖アミノ酸配列を有する、請求項10に記載の方法。
  12. AOIが、配列番号13のアミノ酸配列のVH領域および配列番号14のアミノ酸配列のVL領域を含むIgG1モノクローナル抗体である、請求項1からのいずれか一項に記載の方法。
  13. AOIが、配列番号15の完全重鎖アミノ酸配列および配列番号16の完全軽鎖アミノ酸配列を有する、請求項12に記載の方法。
  14. AOIが、配列番号17のアミノ酸配列のVH領域および配列番号18のアミノ酸配列のVL領域を含むIgG1モノクローナル抗体である、請求項1からのいずれか一項に記載の方法。
  15. AOIが、配列番号19の完全重鎖アミノ酸配列および配列番号20の完全軽鎖アミノ酸配列を有する、請求項14に記載の方法。
JP2015534771A 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法 Active JP6351598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
US61/708,554 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (3)

Publication Number Publication Date
JP2015532096A JP2015532096A (ja) 2015-11-09
JP2015532096A5 true JP2015532096A5 (ja) 2016-11-17
JP6351598B2 JP6351598B2 (ja) 2018-07-04

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534771A Active JP6351598B2 (ja) 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法

Country Status (27)

Country Link
US (2) US20150259425A1 (ja)
EP (1) EP2904092B1 (ja)
JP (1) JP6351598B2 (ja)
KR (1) KR102182885B1 (ja)
CN (1) CN104797707A (ja)
AU (1) AU2013327681B2 (ja)
BR (1) BR112015007319B1 (ja)
CA (1) CA2886753C (ja)
CY (1) CY1119602T1 (ja)
DK (1) DK2904092T3 (ja)
EA (1) EA201590550A1 (ja)
ES (1) ES2646594T3 (ja)
HK (1) HK1207394A1 (ja)
HR (1) HRP20171753T1 (ja)
HU (1) HUE034896T2 (ja)
IL (1) IL237916A0 (ja)
IN (1) IN2015DN02630A (ja)
LT (1) LT2904092T (ja)
ME (1) ME02882B (ja)
MX (1) MX366106B (ja)
NO (1) NO2760138T3 (ja)
PL (1) PL2904092T3 (ja)
PT (1) PT2904092T (ja)
RS (1) RS56641B1 (ja)
SG (2) SG11201502339YA (ja)
SI (1) SI2904092T1 (ja)
WO (1) WO2014055370A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3400241B1 (en) 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
AU2017206012A1 (en) * 2016-01-06 2018-07-26 Outlook Therapeutics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3420072A4 (en) * 2016-02-22 2019-08-28 Agency for Science, Technology and Research CELL CULTURE MEDIUM
US11453858B2 (en) * 2016-11-11 2022-09-27 Whitehead Institute For Biomedical Research Human plasma-like medium
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
EP0970126B1 (en) 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2002066603A2 (en) * 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
CA2560508A1 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
ES2411907T3 (es) 2007-08-03 2013-07-09 Facet Biotech Corporation Uso terapéutico de anticuerpos antirreceptor TWEAK

Similar Documents

Publication Publication Date Title
JP2015532096A5 (ja)
HRP20171753T1 (hr) Pripravci i postupci za proizvodnju glikoproteina
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
EA201900326A1 (ru) Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
JP2016104045A5 (ja)
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
MX2012007497A (es) Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
JP2011525355A5 (ja)
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
JP2013517776A5 (ja)
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
NZ596595A (en) Method for orthopoxvirus production and purification
WO2010013947A3 (ko) 자연살해세포의 증식방법
NZ597742A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
EA202091422A1 (ru) Способ непрерывного производства продуктов на основе биспецифических антител
WO2015010118A3 (en) Transthyretin amyloid-selective and polyreactive catabodies
JP2017520531A5 (ja)
MX2018006627A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
JP2017505620A5 (ja)
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
JP2017508523A5 (ja)
MX2018015234A (es) Métodos para mejorar la transformación genética de sorgo.
AR085271A1 (es) Procedimiento para la produccion a escala comercial de prrsv